Expanded HTA, Legitimacy and Independence Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".
This brief commentary seeks to develop the analysis of Daniels, Porteny and Urrutia of the implications of expansion of the scope of health technology assessment (HTA) beyond issues of safety, efficacy, and cost-effectiveness. Drawing in particular on experience in the United Kingdom, it suggests that such expansion can be understood not only as a response to the problem of insufficiency of evidence, but also to that of legitimacy. However, as expansion of HTA also renders it more visibly political in character, it is plausible that its legitimacy may be undermined, rather than enhanced by, independence from the policy process.
Cardiff School of Law and Politics, Cardiff University, Wales, UK.
Keith
K
Syrett
D003362:Cost-Benefit Analysis; D006801:Humans; D013673:Technology Assessment, Biomedical; D006113:United Kingdom
Budget Impact; Equity; Health Technology Assessment (HTA); Independence; Legitimacy; Regulation; Threshold
Gesundheitswesen. 2001 Apr;63(4):221-5
11367951
BMJ. 1998 Oct 10;317(7164):959-60
9765158
Br J Clin Pharmacol. 2010 Sep;70(3):346-9
20716233
Clin Med (Lond). 2005 Sep-Oct;5(5):471-5
16268329
Int J Technol Assess Health Care. 1995 Spring;11(2):287-300
7790172
J Health Serv Res Policy. 2007 Jan;12(1):56-8
17244400
Health Econ Policy Law. 2013 Apr;8(2):145-65
22717361
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi
25692211
Med Law Rev. 2002 Spring;10(1):1-27
14982079
BMJ. 2004 Jul 24;329(7459):224-7
15271836
J Med Ethics. 2006 Mar;32(3):127-8
16507653
J Health Polit Policy Law. 2001 Apr;26(2):439-46
11330089